NORDICUS PARTNERS CORP - NORD STOCK NEWS

Nordicus Partners (OTCQB: NORD) has announced an agreement to acquire Bio-Convert ApS, a Denmark-based clinical-stage biopharmaceutical company, in an all-stock transaction of 12 million restricted common shares. Bio-Convert specializes in developing treatments for oral leukoplakia, a potentially malignant disorder that can lead to oral cancer. The company is developing a proprietary mucoadhesive oral formulation that delivers medication without systemic absorption, aiming to eliminate lesions or reduce the malignant conversion rate to oral cancer. Bio-Convert plans to conduct a pilot efficacy study in patients with oral leukoplakia.

Nordicus Partners (OTCQB: NORD) announced a 1-for-10 reverse stock split of its common stock, effective November 8, 2024. The company's stock will continue trading on OTCQB under the symbol 'NORD' with a new CUSIP number 28265K 304. The reverse split was approved by stockholders and the Board of Directors on June 7, 2024. Transfer Online, Inc. will act as the transfer agent, and stockholders are not required to take any action as positions will be automatically adjusted.

Nordicus Partners (OTCQB: NORD) will host an investor relations webinar on July 10, 2024, at 9:00 AM Pacific time. The event will feature presentations by CEO Henrik Rouf and Chairman Peter Severin, who will elaborate on the company’s mission and investment strategy. Allan Wehnert, CEO of Nordicus’ 95% subsidiary Orocidin, will update attendees on Orocidin’s scientific progress. Additionally, details about Nordicus’ accelerator client, Bio-Convert, will be discussed. Interested participants can register for the webinar at the provided link.

Nordicus Partners (OTCQB: NORD), a financial consulting firm, has signed a Consultancy Agreement with Danish biopharmaceutical company BIO-CONVERT. BIO-CONVERT specializes in developing treatments for oral leukoplakia, a potentially cancerous condition. The partnership aims to help BIO-CONVERT establish a U.S. market presence. CEO Henrik Rouf expressed optimism about the collaboration and potential equity investment in BIO-CONVERT. BIO-CONVERT's innovative drug, QR-02, uses advanced technology for precise treatment of oral leukoplakia, potentially preventing oral cancer. The company plans a pilot efficacy study for QR-02.

Nordicus Partners , along with its 95% owned subsidiary Orocidin A/S, announced new insights into the treatment of periodontitis via their preclinical product QR-01. QR-01 is aimed at treating bacterial infections and normalizing immunological functions in periodontitis patients. The product has antimicrobial, immunomodulatory, and antibiofilm properties. It is formulated in a thermosensitive gel that solidifies at mouth temperature, allowing bi-weekly administration. Orocidin plans to start clinical trials for QR-01 in Q4, 2024.

Nordicus Partners (OTCQB: NORD), a financial consulting firm, has appointed Peter Severin as Chairman of the Board of Directors. Severin replaces Christian Hill-Madsen, who resigned to focus on developing periodontitis therapies for Orocidin A/S, a company predominantly owned by Nordicus. CEO Henrik Rouf expressed confidence in Severin’s extensive sales experience in the Nordic life sciences sector, which is expected to benefit Nordicus's strategy of acquiring majority stakes in Nordic and U.S. life sciences companies.

Nordicus Partners (OTCQB: NORD) has acquired a 95% stake in Orocidin A/S as of May 15, 2024. The company has also engaged FORCE Family Office to enhance investor awareness. FORCE will help Nordicus by promoting its story to a vast network of family offices, foundations, and endowments through webinars and events. CEO Henrik Rouf expressed optimism about working with FORCE to attract sophisticated Life Sciences investors. Steven Saltzstein, CEO of FORCE, praised Nordicus for connecting top Nordic scientists with the U.S. capital market, expecting significant value creation from this collaboration.

Nordicus Partners (OTCQB: NORD) has acquired a 95% stake in Orocidin A/S, a clinical-stage biopharmaceutical company specializing in periodontitis therapies, for $38 million. The transaction involves issuing 38 million restricted common shares to Orocidin’s shareholders. As a result, Nordicus CEO Henrik Rouf and Director Henrik Keller will join Orocidin's Board of Directors. This acquisition aligns with Nordicus's strategy to support innovative life sciences companies in entering the U.S. market. Orocidin’s key product, QR-01, is designed to combat periodontitis, addressing a significant unmet need in a market projected to reach $1.3 billion by 2029.

Nordicus Partners (OTCQB: NORD) has announced its uplisting to the OTCQB, a recognized public securities market by the SEC. This move aims to enhance liquidity, achieve fair valuation, and attract a wider network of investors and media partners. The uplisting is expected to aid in executing growth plans and making shares more appealing to potential targets.